|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Sat., Mar. 28, 7:01 AM
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Secondary Stock Offerings| This Slide: #22 of 25 |
Slide #22. EyePoint Pharmaceuticals, Inc. — Secondary Offering
Company:
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Date announced:
2/20/2020
Shares Offered:
15,000,000
Date of Pricing:
2/21/2020
Price Per Share:
$1.45
Secondary Offering Details:
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, EyePoint intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering. -updated 2/21- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $1.45 per share. The gross proceeds of the offering to the Company are expected to be approximately $21,750,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, EyePoint granted the underwriters a thirty-day option to purchase up to an additional 2,250,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
EyePoint Pharmaceuticals is a biopharmaceutical company focuses on developing and commercializing ophthalmic products for the treatment of eye diseases. YUTIQ™ (fluocinolone acetonide intravitreal implant) is used for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIPU). DEXYCU™ (dexamethasone intraocular suspension) is used for the treatment of post-operative ocular inflammation. Co. is entitled to royalties pursuant to license and collaboration agreements utilizing its Durasert technology platform. These include ILUVIEN® for the treatment of diabetic macular edema, ILUVIEN for NIPU, and Retisert® for the treatment of posterior segment uveitis.
Open the EYPT Page at The Online Investor »
|
|||||||||||||||||||||
Open the EYPT Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Buy (3.33 out of 4) 57th percentile
(ranked higher than approx. 57% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.